AIRLINK 61.60 Decreased By ▼ -0.88 (-1.41%)
BOP 5.35 Decreased By ▼ -0.01 (-0.19%)
CNERGY 4.48 Decreased By ▼ -0.10 (-2.18%)
DFML 15.35 Decreased By ▼ -0.15 (-0.97%)
DGKC 65.24 Decreased By ▼ -1.16 (-1.75%)
FCCL 17.23 Decreased By ▼ -0.36 (-2.05%)
FFBL 27.50 Decreased By ▼ -0.20 (-0.72%)
FFL 9.28 Increased By ▲ 0.01 (0.11%)
GGL 10.01 Decreased By ▼ -0.05 (-0.5%)
HBL 105.00 Decreased By ▼ -0.70 (-0.66%)
HUBC 121.44 Decreased By ▼ -0.86 (-0.7%)
HUMNL 6.50 Decreased By ▼ -0.10 (-1.52%)
KEL 4.43 Decreased By ▼ -0.07 (-1.56%)
KOSM 4.35 Decreased By ▼ -0.13 (-2.9%)
MLCF 35.44 Decreased By ▼ -0.76 (-2.1%)
OGDC 122.50 Decreased By ▼ -0.42 (-0.34%)
PAEL 22.79 Decreased By ▼ -0.21 (-0.91%)
PIAA 31.35 Increased By ▲ 2.01 (6.85%)
PIBTL 5.80 No Change ▼ 0.00 (0%)
PPL 107.00 Decreased By ▼ -0.50 (-0.47%)
PRL 27.20 Decreased By ▼ -0.05 (-0.18%)
PTC 17.95 Decreased By ▼ -0.12 (-0.66%)
SEARL 52.68 Decreased By ▼ -0.32 (-0.6%)
SNGP 62.62 Decreased By ▼ -0.59 (-0.93%)
SSGC 10.60 Decreased By ▼ -0.20 (-1.85%)
TELE 9.05 Decreased By ▼ -0.15 (-1.63%)
TPLP 11.42 Decreased By ▼ -0.02 (-0.17%)
TRG 70.20 Decreased By ▼ -0.66 (-0.93%)
UNITY 23.55 Decreased By ▼ -0.07 (-0.3%)
WTL 1.28 No Change ▼ 0.00 (0%)
BR100 6,913 Decreased By -30.9 (-0.45%)
BR30 22,661 Decreased By -166.2 (-0.73%)
KSE100 66,937 Decreased By -205.1 (-0.31%)
KSE30 22,030 Decreased By -59.5 (-0.27%)

Pfizer Inc and partner BioNTech have completed the filing with the US drugs regulator seeking authorization for their COVID-19 vaccine in children under 5 years of age.

The filing with the US Food and Drug Administration (FDA), completed on Wednesday, included data showing three lower-dose shots of the vaccine generated a strong immune response in children as young as 6 months of age.

No COVID-19 shot is yet approved for children in that age group in most parts of the world. It remains unclear how many parents will get their young ones vaccinated as demand has been low in kids aged 5 to 11.

US doctors reconsider Pfizer’s Paxlovid for lower-risk COVID patients

Pfizer and BioNTech on May 23 said their trial showed a 3 microgram version of the vaccine generated a similar immune response in under 5-year-olds as two doses of 30 micrograms each in 16 to 25-year-olds in an earlier trial.

Rival Moderna in March released trial data that showed a two-dose formulation of its vaccine was safe and generated a similar immune response in young children as in adults.

The FDA’s independent advisers will discuss the two applications in a meeting set for June 15.

Comments

Comments are closed.